The approval was based on data from the LEGACY study, a single-arm, retrospective trial that evaluated treatment with TheraSphere Y90 glass microspheres in 162 patients with unresectable hepatocellular carcinoma.
There is a need for interventions to increase HCC surveillance in patients with cirrhosis due to a high proportion of late-stage detection.
Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
A team of researchers created a machine learning system to identify liver toxicity related to chemical compounds used in a rat model.
A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients.
The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
The combination resulted in durable response in many patients.
The source of fats in an individual’s diet may alter the risk of developing hepatocellular carcinoma.
For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life.
Intolerance to treatment with direct acting antiviral treatment was found to be associated with older age and advanced liver disease in patients with hepatocellular carcinoma.
The median change in HCC tumor size between responders and nonresponders was statistically significant.
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.
The review authors used existing evidence to recommend a new model of palliative care integration in patients with hepatocellular carcinoma.
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
PHGDH may be a possible target for overcoming sorafenib resistance, preclinical evidence suggests.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to SFA001 (SFA Therapeutics) for the treatment of hepatocellular carcinoma (HCC).
According to a recently published study, a high level of hepatitis B core-related antigen is a complementary risk factor for hepatocellular carcinoma development.
Leisure-time physical activity at recommended levels is associated with a significantly lower risk for seven cancer types.
From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.